Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | UTHR |
---|---|---|
09:32 ET | 2628 | 265.93 |
09:39 ET | 600 | 265.305 |
09:41 ET | 310 | 266.04 |
09:48 ET | 1100 | 267.08 |
09:50 ET | 1014 | 267.105 |
09:54 ET | 1034 | 266.74 |
09:56 ET | 1000 | 266.26 |
09:57 ET | 130 | 266.84 |
09:59 ET | 100 | 266.4233 |
10:01 ET | 300 | 265.98 |
10:03 ET | 300 | 266.01 |
10:06 ET | 100 | 266.12 |
10:08 ET | 400 | 266.12 |
10:10 ET | 500 | 266.36 |
10:12 ET | 200 | 266.36 |
10:14 ET | 1939 | 266.635 |
10:15 ET | 1562 | 266.58 |
10:17 ET | 809 | 266.38 |
10:19 ET | 200 | 266.17 |
10:24 ET | 100 | 266.08 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
United Therapeutics Corp | 11.7B | 12.6x | +8.22% |
Exact Sciences Corp | 9.9B | -41.6x | --- |
Medpace Holdings Inc | 12.1B | 40.1x | +35.10% |
Biomarin Pharmaceutical Inc | 15.4B | 77.0x | --- |
Qiagen NV | 9.7B | 28.9x | +12.66% |
Neurocrine Biosciences Inc | 13.8B | 37.8x | +62.04% |
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.7B |
---|---|
Revenue (TTM) | $2.5B |
Shares Outstanding | 44.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $21.13 |
Book Value | $127.23 |
P/E Ratio | 12.6x |
Price/Sales (TTM) | 4.7 |
Price/Cash Flow (TTM) | 10.6x |
Operating Margin | 50.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.